The Adverse Event Paradox

Authors

DOI:

https://doi.org/10.5195/pom.2022.119

Keywords:

Adverse Event, Placebo Effect, Nocebo Effect, Randomized Controlled Trials

References

Beigel, John H., Kay M. Tomashek, Lori E. Dodd, Aneesh K. Mehta, Barry S. Zingman, Andre C. Kalil, Elizabeth Hohmann, et al. 2020. “Remdesivir for the Treatment of Covid-19: Final Report.” New England Journal of Medicine 383, no. 19: 1813–1826. https://doi.org/10.1056/nejmoa2007764.

Bolton, Monica, Alex Hodkinson, Shivani Boda, Alan Mould, Maria Panagioti, Sarah Rhodes, Lisa Riste, and Harm van Marwijk. 2019. “Serious Adverse Events Reported in Placebo Randomised Controlled Trials of Oral Naltrexone: A Systematic Review and Meta-Analysis.” BMC Medicine 17, no. 1: 1–13. https://doi.org/10.1186/s12916-018-1242-0.

Colloca, Luana and Franklin G. Miller. 2011. “The Nocebo Effect and Its Relevance for Clinical Practice.” Psychosomatic Medicine 73, no. 7: 598–603. https://doi.org/10.1097/psy.0b013e3182294a50.

Hammond, Jennifer, Heidi Leister-Tebbe, Annie Gardner, Paula Abreu, Weihang Bao, Wayne Wisemandle, MaryLynn Baniecki, et al. 2022. “Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.” New England Journal of Medicine 386, no. 15: 1397–1408. https://doi.org/10.1056/nejmoa2118542.

Kirsch, Irving. 2010. The Emperor’s New Drugs: Exploding the Antidepressant Myth. New York: Basic Books.

Wang, Yeming, Dingyu Zhang, Guanhua Du, Ronghui Du, Jianping Zhao, Yang Jin, Shouzhi Fu, et al. 2020. “Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial.” The Lancet 395, no. 10236: 1569–1578. https://doi.org/10.1016/s0140-6736(20)31022-9.

Downloads

Published

2022-05-16

How to Cite

Milovac, T. (2022). The Adverse Event Paradox . Philosophy of Medicine, 3(1). https://doi.org/10.5195/pom.2022.119

Issue

Vol. 3 No. 1 (2022)

Section

Letters

License

Authors who publish with this journal agree to the following terms:

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
    with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
  4. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
  5. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
  6. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
  7. The Author represents and warrants that:
    1. the Work is the Author’s original work;
    2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
    3. the Work is not pending review or under consideration by another publisher;
    4. the Work has not previously been published;
    5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
    6. the Work contains no libel, invasion of privacy, or other unlawful matter.
  8. The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
  9. The Author agrees to digitally sign the Publisher’s final formatted PDF version of the Work.